ERBB2 and non-small cell lung carcinoma: Among 436 tested NSCLC samples, five specimens (1.15%) showed a significantly higher ratio of MET to both reference loci (p ≤ 0.025), and six samples (1.38%) demonstrated a higher ratio of HER2 (p ≤ 0.05).